Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between 18 and 75 years~* Documented history of ileal, colonic, or ileocolonic CD~* CDAI score ≥ 220 to ≤ 450~* Evidence of active inflammation as demonstrated by endoscopic confirmation of active disease~* Subjects previously not exposed to anti-TNF treatment (TNF-naïve) or subjects previously exposed to anti-TNF therapy at a registered dose, that has been discontinued at least 8 weeks prior to Screening and deemed by the treating physician as a primary or secondary non-responder or intolerant (TNF-experienced)~* Continuation of concurrent treatment with oral steroids (≤30 mg prednisolone eq/day), mesalazine, olsalazine, CD-related antibiotics and probiotics at stable dose is allowed~* Previous exposure to immunomodulators is permitted, but must be discontinued~* Haematology and biochemistry lab parameters within predefined ranges as stated in the protocol~Exclusion Criteria:~* Diagnosis of indeterminate colitis, ulcerative colitis (UC), or clinical findings suggestive of UC~* Stoma, gastric or ileoanal pouch, procto- or total colectomy, symptomatic stenosis or obstructive strictures, history of bowel perforation, (suspected) abscess; actively draining fistulae~* Subject who has had surgical bowel resections within the past 6 months, short bowel syndrome or is receiving tube feeding, defined formula diets, or parenteral alimentation~* Subject with positive Clostridium difficile toxin stool assay or evidence of any other gastrointestinal infection~* Subject who has received non-permitted IBD therapies within specified timeframes, depending on the medication, as stated in the protocol~* Subject with a (previous history of) dysplasia of the gastrointestinal tract~* Concurrent gastro-intestinal malignancy or a history of cancer elsewhere~* History of lymphoproliferative disease~* Known active infection of any kind, current therapy for chronic infection or history of specific infections as stated in the protocol~* Subject who is pregnant, lactating or not willing to maintain highly effective birth control methods during the course of the study and 12 weeks thereafter

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- GLPG0634 200 mg QD (Type: EXPERIMENTAL): 2 tablets of 100 mg GLPG0634 in the morning
- GLPG0634 100 mg QD (Type: EXPERIMENTAL): 1 tablet of 100 mg GLPG0634 and 1 placebo tablet in the morning
- Placebo QD (Type: PLACEBO_COMPARATOR): 2 placebo tablets in the morning

Based on this trial design, predict the completion outcome and termination type (if applicable).